in vivo News and Research

RSS

Nanoparticles do not penetrate beneath outermost layer of cells when applied to the skin

Ultra-tiny zinc oxide (ZnO) particles with dimensions less than one-ten-millionth of a meter are among the ingredients list of some commercially available sunscreen products, raising concerns about whether the particles may be absorbed beneath the outer layer of skin.

1 Dec 2011

Researchers create bone-like material and structure for orthopedic procedures

It looks like bone. It feels like bone. For the most part, it acts like bone. And it came off an inkjet printer. Washington State University researchers have used a 3D printer to create a bone-like material and structure that can be used in orthopedic procedures, dental work, and to deliver medicine for treating osteoporosis. Paired with actual bone, it acts as a scaffold for new bone to grow on and ultimately dissolves with no apparent ill effects.

30 Nov 2011

Scientists identify cellular protein that plays central role in formation of new blood vessels

Scientists at the University of North Carolina at Chapel Hill School of Medicine have identified a cellular protein that plays a central role in the formation of new blood vessels.

29 Nov 2011

Selcia completes 14C radiolabelled API projects for clients

Selcia has successfully completed 14C radiolabelled API projects on behalf of a diverse range of clients for phase 1 human trials, following MHRA GMP Certification in September 2010. In response to a sharp increase in demand for this specialist service, Selcia has invested to double its capacity for handling GMP radiolabelling projects.

29 Nov 2011

Study reveals PEA-15 protein can enhance cancer cell proliferation

A new study from the University of Hawaii Cancer Center reveals that PEA-15, a protein previously shown to slow ovarian tumor growth and metastasis, can alternatively enhance tumor formation in kidney cells carrying a mutation in a cancer-promoting gene called H-Ras.

22 Nov 2011

Adeona to develop and commercialize DNA-based therapeutic for PAH using Intrexon technology

Adeona Pharmaceuticals, Inc., and the Human Therapeutics Division of Intrexon Corporation, announced today the formation of a global exclusive channel collaboration through which Adeona intends to develop and commercialize a DNA-based therapeutic using Intrexon's UltraVector platform and RheoSwitch Therapeutic System for the treatment of pulmonary arterial hypertension (PAH).

21 Nov 2011

CTI receives U.S. Patent Allowance for GlycoPolymer technology

Cell Therapeutics, Inc. (CTI) announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application directed to increasing the plasma half-life of therapeutic proteins and peptides by recombinantly conjugating them to a novel, non-immunogenic peptide repeat sequence.

21 Nov 2011

Scientists identify novel gene mutation that causes glioblastoma

Scientists at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center, in collaboration with colleagues in Boston and South Korea, say they have identified a novel gene mutation that causes at least one form of glioblastoma (GBM), the most common type of malignant brain tumor.

18 Nov 2011

NYU Langone cardiovascular experts present new research findings at AHA 2011

Experts from the Cardiac & Vascular Institute at NYU Langone Medical Center presented new research findings at the American Heart Association Scientific Sessions 2011 held November 12-16, 2011 in Orlando, Florida.

18 Nov 2011

Aileron, Roche to expand Stapled Peptide drug collaboration

Aileron Therapeutics announced today that Roche will initiate a new program to expand its collaboration with Aileron to discover, develop and commercialize Stapled Peptide drugs.

16 Nov 2011

ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today new preclinical data from two separate studies of darinaparsin, a novel organic arsenic, in various solid tumor models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

16 Nov 2011

New paper shows how platelets help promote cancer metastasis

About 90 percent of cancer deaths are caused by secondary tumors, known as metastases, which spread from the original tumor site. To become mobile and break free from the original tumor, cancer cells need help from other cells in their environment. Many cells have been implicated in this process, including immune system cells and cells that form connective tissue. Another collaborator in metastasis is platelets, the blood cells whose normal function is to promote blood clotting.

16 Nov 2011

InVivo Therapeutics reports net income of $3,067,000 for third quarter 2011

InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today reported financial results for the three and nine months ended September 30, 2011 and provided a business update.

15 Nov 2011

Fetal stem cells play an important role in inducing maternal cardiac repair

Researchers from Mount Sinai School of Medicine have discovered the therapeutic benefit of fetal stem cells in helping the maternal heart recover after heart attack or other injury.

14 Nov 2011

Top-line results from Probiodrug's PQ912 Phase 1 SAD, MAD study for Alzheimer's disease

Probiodrug AG, a biotech company developing products for the treatment of neurodegenerative and inflammatory diseases, with a particular focus on Alzheimer's disease (AD), today announced top-line results of its Phase 1 single (SAD) and multiple ascending dose (MAD) study of PQ912 in healthy volunteers.

14 Nov 2011

Concert to initiate CTP-499 Phase 2 diabetic nephropathy clinical trial in 2012

Concert Pharmaceuticals, Inc. today announced data from a Phase 1 clinical trial of CTP-499, a novel agent for the potential treatment of diabetic nephropathy.

14 Nov 2011

Scientists create new phenotypic cancer drug screening platform

Researchers have created a new phenotypic screening platform that better predicts success of drugs developed to prevent blood vessel tumor growth when moving out of the lab and onto actual tumors.

14 Nov 2011

New genetic approach to treat fibrodysplasia ossificans progressiva

Scientists at Penn's Perelman School of Medicine Center for Research in FOP and Related Disorders have developed a new genetic approach to specifically block the damaged copy of the gene for a rare bone disease, while leaving the normal copy untouched.

9 Nov 2011

InfraReDx TVC Imaging System to be exhibited at TCT 2011

InfraReDx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases, today announced that its TVC Imaging System for the true vessel characterization of coronary artery disease will be highlighted during the annual Transcatheter Cardiovascular Therapeutics Meeting (TCT 2011).

7 Nov 2011

Einstein scientists receive two NCI grants to study cancer metastasis

The National Cancer Institute (NCI) has awarded Albert Einstein College of Medicine of Yeshiva University two grants totaling $8 million to study the microenvironments that drive the spread of cancer from the primary tumor to other parts of the body in the process known as metastasis.

4 Nov 2011